Clinical Trial: SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141329) titled 'SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures' on Aug. 19.

Brief Summary: This is a Phase 3 open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Study Start Date: July 30

Study Type: INTERVENTIONAL

Condition: Focal Onset Seizures

Intervention: DRUG: SPN-817

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

Recruitment Status: RECRUITING

Sponsor: Supernus Pharmaceuticals, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....